About the Immunotherapy: Checkpoint inhibitors, CAR-T cell therapy, and vaccine-based treatments. Session
Immunotherapy represents a paradigm shift in cancer treatment, harnessing the body’s immune system to combat tumors. Case studies featuring therapies like checkpoint inhibitors, CAR-T cells, and cancer vaccines demonstrate their transformative potential. For example, pembrolizumab’s success in treating metastatic melanoma has opened doors for its use in other cancers. These cases also highlight challenges, such as managing immune-related adverse events and identifying biomarkers to predict response. By documenting successes and obstacles, these studies provide a roadmap for refining immunotherapy and expanding its application to more cancer types, ultimately improving patient outcomes.
Topics Covered in Immunotherapy: Checkpoint inhibitors, CAR-T cell therapy, and vaccine-based treatments.
Checkpoint Blockade
Engineered T Cells
Therapeutic Cancer Vaccines
Response Biomarkers
Immune Toxicity Management
Treatment Resistance
Related Scientific Sessions at CIOC 2027
Why Attend the Immunotherapy: Checkpoint inhibitors, CAR-T cell therapy, and vaccine-based treatments. Conference 2027
Earn CPD Credit
Sessions are CPD-accredited; certificates issued to every registered delegate within two weeks of the conference.
Present Your Research
Oral and poster slots for original Immunotherapy: Checkpoint inhibitors, CAR-T cell therapy, and vaccine-based treatments. work, reviewed by the scientific committee.
Network Globally
Meet oncologists, cancer researchers, and clinical specialists from around the world across three days.
Publish & Get Indexed
Accepted abstracts appear in the indexed conference proceedings with a citable DOI.
Learn from Keynotes
Plenary lectures from leading voices shaping Immunotherapy: Checkpoint inhibitors, CAR-T cell therapy, and vaccine-based treatments. research and practice.
Hybrid Flexibility
Attend in person in Singapore or join virtually — same programme, same certificate.
Join CIOC 2027 for the Immunotherapy: Checkpoint inhibitors, CAR-T cell therapy, and vaccine-based treatments. track
Oral and poster slots for your work — in person in Singapore or online. Not presenting? Attend as a delegate to learn from the field.
Immunotherapy: Checkpoint inhibitors, CAR-T cell therapy, and vaccine-based treatments. Conference 2027 — FAQs
What is the Immunotherapy: Checkpoint inhibitors, CAR-T cell therapy, and vaccine-based treatments. track at CIOC 2027?
The Immunotherapy: Checkpoint inhibitors, CAR-T cell therapy, and vaccine-based treatments. track is a dedicated stream within CIOC 2027 covering the latest research, clinical innovation, and best practice in Immunotherapy: Checkpoint inhibitors, CAR-T cell therapy, and vaccine-based treatments.. It brings together researchers, educators, and practitioners for oral presentations, posters, and discussion.
Who should attend the Immunotherapy: Checkpoint inhibitors, CAR-T cell therapy, and vaccine-based treatments. sessions?
Cancer researchers and clinicians, educators and students with an interest in Immunotherapy: Checkpoint inhibitors, CAR-T cell therapy, and vaccine-based treatments. are all welcome — whether presenting or attending.
Can I present my research in the Immunotherapy: Checkpoint inhibitors, CAR-T cell therapy, and vaccine-based treatments. track?
Yes. Submit an abstract for oral or poster presentation. All submissions are peer-reviewed by the scientific committee; accepted abstracts appear in the indexed proceedings.
Is virtual attendance available for Immunotherapy: Checkpoint inhibitors, CAR-T cell therapy, and vaccine-based treatments. sessions?
Yes. CIOC 2027 is a hybrid conference — attend the Immunotherapy: Checkpoint inhibitors, CAR-T cell therapy, and vaccine-based treatments. track in person in Singapore or join live online, with on-demand access afterward.
Join the CIOC 2027 delegation
Singapore · March 15–17, 2027· Hybrid · in-person & virtual
Attend without presenting.